AVBP — ArriVent BioPharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1868279 ·
Last close
$10.69
Market Cap
$552.92M
52W High
$35.83
52W Low
$10.49
ADV30
1,513,685
Next earnings
2026-11-16
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -48,376,000 -45,313,000 417,089,000 113,583,000 23,613,000
Jun 2026 0 — -52,691,000 -49,893,000 394,718,000 154,682,000 27,877,000
Mar 2026 0 — -46,111,000 -43,320,000 349,295,000 62,103,000 25,315,000
Dec 2025 0 — -38,823,000 -35,544,000 333,169,000 45,540,000 25,945,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-152,841,000
Investing CF
$-82,197,000
Financing CF
$235,949,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.65
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-538,167,000
Inventory
—
Receivables
$60,000
ST Investments
$279,640,000
EBIT TTM
$-186,001,000
Pretax Income TTM
$-174,070,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,000,000
EBITDA
—
Free Cash Flow
$-91,454,000
Enterprise Value
$279,950,208
Total Cash
$393,223,008
Total Debt
$256,000
Shares Out
51,723,074
Trailing EPS
$-3.60
Book Value
$7.68
ROE
-48.7%
ROA
-30.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -177,534,000 -166,308,000 333,169,000 25,945,000 307,224,000 -160,588,000
Dec 2024 0 -94,308,000 -80,488,000 274,942,000 17,288,000 257,654,000 -70,212,000
Dec 2023 0 -74,590,000 -69,333,000 163,098,000 316,291,000 -153,193,000 -55,842,000
Dec 2022 0 -36,906,000 -36,906,000 182,833,000 267,942,000 -85,109,000 -43,631,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-163,735,000
OpCashFlow TTM
—
Assets (Latest)
$394,718,000
Forward EPS
$-3.62

Peers — same industry

TickerNameMarket CapLastDaily %
ANL Adlai Nortye Group Ltd. $556.80M $9.48 —
ZVRA ZEVRA THERAPEUTICS, INC. $559.34M $9.40 —
WVE Wave Life Sciences, Inc. $560.13M $2.84 —
ACRS Aclaris Therapeutics, Inc. $536.11M $3.38 —
CLYM Climb Bio, Inc. $574.46M $9.78 —

News headlines (Yahoo Finance, 1h cache)

ArriVent BioPharma Reports Third Quarter 2026 Financial Results
2026-11-09 21:01 · Yahoo
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
2026-10-27 04:02 · Yahoo
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
2026-10-27 01:08 · Yahoo
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
2026-10-25 13:00 · Yahoo
Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe
2026-10-24 12:14 · Yahoo
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
2026-10-23 20:00 · Yahoo
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
2026-10-19 12:01 · Yahoo
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
2026-10-12 20:01 · Yahoo
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
2026-10-08 05:38 · Yahoo
ArriVent’s stock plummets on Phase III NSCLC trial failure
2026-10-07 14:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.